Related Experiment Video
Updated: Aug 9, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
[Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication]
J A M van Laar1, A Jamnitski, G S Baarsma
1Erasmus MC-Dijkzigt, afd. Inwendige Geneeskunde, sectie Immunologie, afd. Immunologie, Dr.Molewaterplein 40, 3015 GD Rotterdam. j.vanlaar@erasmusmc.nl
Abstract:
A 25-year-old woman was admitted after having had a fever for one month, headache, nausea, vomiting, dysarthria and right-sided hemiparesis. A 35-year-old man was admitted because of severe loss of vision and a history of focal retinochoroiditis. Both were suffering from Behçet's disease. Behçet's disease can present with systemic symptoms that might be related to aberrant T-cell functions. It is treated with a variety of immunoregulatory drugs. Recently, treatment with tumour necrosis factor (TNF) alpha-inhibiting molecular designed drugs such as infliximab or etanercept has improved the therapeutic prospective of Behçet patients. Both of the patients described above developed refractory disease and responded to treatment with these new drugs.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Tumor Microenvironment
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
